Trinity Biotech plc (TRIB)
NASDAQ: TRIB · Real-Time Price · USD
0.6054
-0.0136 (-2.20%)
Apr 7, 2026, 4:00 PM EDT - Market closed
Trinity Biotech Revenue
Trinity Biotech had revenue of $14.31M in the quarter ending September 30, 2025, a decrease of -5.54%. This brings the company's revenue in the last twelve months to $48.57M, down -17.85% year-over-year. In the year 2024, Trinity Biotech had annual revenue of $61.56M with 8.31% growth.
Revenue (ttm)
$48.57M
Revenue Growth
-17.85%
P/S Ratio
0.23
Revenue / Employee
$121,122
Employees
401
Market Cap
11.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 61.56M | 4.72M | 8.31% |
| Dec 31, 2023 | 56.83M | -5.69M | -9.10% |
| Dec 31, 2022 | 62.52M | -18.63M | -22.96% |
| Dec 31, 2021 | 81.15M | -20.83M | -20.43% |
| Dec 31, 2020 | 101.98M | 11.55M | 12.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IRIDEX | 52.68M |
| Vivos Therapeutics | 17.32M |
| Pulsenmore | 12.55M |
| Beyond Air | 6.92M |
| Biomerica | 4.46M |
| Tenon Medical | 3.94M |
| Sintx Technologies | 1.02M |
| Nexalin Technology | 301.65K |
TRIB News
- 15 days ago - Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test - GlobeNewsWire
- 20 days ago - Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome - GlobeNewsWire
- 26 days ago - Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System - GlobeNewsWire
- 27 days ago - Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program - GlobeNewsWire
- 4 weeks ago - Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform - GlobeNewsWire
- 4 weeks ago - Trinity Biotech Provides Business and Trading Update - GlobeNewsWire
- 5 weeks ago - Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives - GlobeNewsWire
- 6 weeks ago - Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares - GlobeNewsWire